Sean Sachdev
Expertise in
24
conditions

Dr. Sean Sachdev

Radiation Oncology
251 E Huron St Ste LC-178, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
15 Years of Experience
Referral may be required
Expertise in
24
conditions
251 E Huron St Ste LC-178, Galter Pavilion, 
Chicago, IL 

Overview

Sean Sachdev is a Radiation Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 15 years.

Dr. Sachdev is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Prostate Cancer, Gamma Knife Radiosurgery, and Prostatectomy.

Dr. Sachdev is board certified in American Board Of Radiology - Radiation Oncology (Certified). He is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 6 clinical trials.

Graduate Institution

Stanford University School Of Medicine, 2011.0

Residency

McGaw Medical Center of Northwestern University

Specialties

Radiation Oncology

Licenses

Radiology in IL

Board Certifications

American Board Of Radiology - Radiation Oncology (Certified)

Hospital Affiliations

Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

251 E Huron St Ste LC-178, Galter Pavilion, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: April 06, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
View 5 Less Clinical Trials

104 Total Publications

Performance of deep learning-based segmentation of soft tissue sarcoma by MRI sequence, tumor type and location.
Performance of deep learning-based segmentation of soft tissue sarcoma by MRI sequence, tumor type and location.
Journal: Skeletal radiology
Published: November 28, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Vinai Gondi
Radiation Oncology
Expertise in
34
conditions
Dr. Vinai Gondi
Radiation Oncology
4405 Weaver Pkwy, 
Waterman, IL 
 (29.6 miles away)
815-334-5566
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vinai Gondi is a Radiation Oncologist practicing medicine in Waterman, Illinois. He has been practicing medicine for over 19 years. Dr. Gondi is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Astrocytoma, Glioblastoma, Glioma, and Gamma Knife Radiosurgery. Dr. Gondi is board certified in American Board Of Radiology - Radiation Oncology (Certified).

Expertise in
10
conditions
Dr. Stanley Liauw
Radiation Oncology
Expertise in
10
conditions
Dr. Stanley Liauw
Radiation Oncology

University Of Chicago Hospitals

5758 S Maryland Ave, 
Chicago, IL 
 (7.3 miles away)
855-702-8222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stanley Liauw is a Radiation Oncologist practicing medicine in Chicago, Illinois. Dr. Liauw is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Anal Cancer, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Expertise in
26
conditions
Dr. Dian Wang
Radiation Oncology
Expertise in
26
conditions
Dr. Dian Wang
Radiation Oncology

Office

500 S Paulina St, 
Chicago, IL 
 (3.2 miles away)
312-942-5751
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dian Wang is a Radiation Oncologist practicing medicine in Chicago, Illinois. Dr. Wang is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Myxoid Liposarcoma, Familial Prostate Cancer, Vaginectomy, and Nephrectomy.

Frequently Asked Questions about Dr. Sean Sachdev

How do I make an appointment with Dr. Sean Sachdev?

You can book an appointment with Dr. Sean Sachdev by calling their office at 312-926-2520. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sean Sachdev a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sean Sachdev is classified as an Distinguished expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sean Sachdev specialize in?

While Dr. Sean Sachdev is a Radiation Oncology, they have specific expertise in Glioblastoma, Astrocytoma, and Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Sean Sachdev participate in research or clinical trials?

Yes. Dr. Sean Sachdev has published 104 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Sean Sachdev's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sean Sachdev accept my insurance?

Dr. Sean Sachdev accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 312-926-2520 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sachdev's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile